[{"id":"dc690118-6ca4-4812-9ba9-2f56494fb793","acronym":"GO29781","url":"https://clinicaltrials.gov/study/NCT02500407","created_at":"2021-01-18T12:03:14.142Z","updated_at":"2025-02-25T14:06:51.320Z","phase":"Phase 1/2","brief_title":"A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT02500407 - GO29781","lead_sponsor":"Genentech, Inc.","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 713","initiation":"Initiation: 09/15/2015","start_date":" 09/15/2015","primary_txt":" Primary completion: 05/21/2024","primary_completion_date":" 05/21/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-18"},{"id":"f3d0b4ce-a825-4e88-abe6-0a2852f91550","acronym":"SUNMO","url":"https://clinicaltrials.gov/study/NCT05171647","created_at":"2021-12-29T14:53:50.426Z","updated_at":"2025-02-25T14:41:08.199Z","phase":"Phase 3","brief_title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05171647 - SUNMO","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • oxaliplatin • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 04/25/2022","start_date":" 04/25/2022","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-14"},{"id":"0a2b6dbc-36dd-467c-bb46-4e7fcb611199","acronym":"CO41942","url":"https://clinicaltrials.gov/study/NCT04246086","created_at":"2023-03-27T23:03:02.854Z","updated_at":"2025-02-25T15:34:35.235Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma","source_id_and_acronym":"NCT04246086 - CO41942","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 237","initiation":"Initiation: 08/12/2020","start_date":" 08/12/2020","primary_txt":" Primary completion: 10/15/2028","primary_completion_date":" 10/15/2028","study_txt":" Completion: 10/15/2030","study_completion_date":" 10/15/2030","last_update_posted":"2025-02-10"},{"id":"2dc4eb4c-eda6-4d7f-bf25-c974b4ee8106","acronym":"CO43805","url":"https://clinicaltrials.gov/study/NCT05169515","created_at":"2021-12-27T15:54:16.180Z","updated_at":"2025-02-25T15:27:09.973Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05169515 - CO43805","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • iberdomide (CC-220) • Columvi (glofitamab-gxbm) • golcadomide (CC-99282)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 03/07/2027","primary_completion_date":" 03/07/2027","study_txt":" Completion: 03/07/2029","study_completion_date":" 03/07/2029","last_update_posted":"2025-02-10"},{"id":"9a9ff008-2d0b-4d26-91f5-d8f2ec4ab9cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672251","created_at":"2023-01-05T14:58:29.816Z","updated_at":"2025-02-25T16:39:34.057Z","phase":"Phase 2","brief_title":"Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT05672251","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynlonta (loncastuximab tesirine-lpyl) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/02/2024","start_date":" 01/02/2024","primary_txt":" Primary completion: 04/22/2025","primary_completion_date":" 04/22/2025","study_txt":" Completion: 04/22/2025","study_completion_date":" 04/22/2025","last_update_posted":"2025-02-06"},{"id":"eb87323c-0942-4abb-b43f-af01b1dff7f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015880","created_at":"2023-12-26T19:17:43.252Z","updated_at":"2025-02-25T17:32:19.406Z","phase":"Phase 1","brief_title":"Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT06015880","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CD79B • CD4","pipe":" | ","alterations":" CD79B expression","tags":["IFNG • CD79B • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/20/2024","start_date":" 05/20/2024","primary_txt":" Primary completion: 06/29/2026","primary_completion_date":" 06/29/2026","study_txt":" Completion: 06/29/2026","study_completion_date":" 06/29/2026","last_update_posted":"2025-01-30"},{"id":"82776520-b06e-46e0-b799-6acc9cecb384","acronym":"","url":"https://clinicaltrials.gov/study/NCT05615636","created_at":"2022-11-14T14:58:16.761Z","updated_at":"2024-07-02T16:34:36.912Z","phase":"Phase 2","brief_title":"A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL","source_id_and_acronym":"NCT05615636","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/28/2023","start_date":" 04/28/2023","primary_txt":" Primary completion: 08/19/2025","primary_completion_date":" 08/19/2025","study_txt":" Completion: 08/19/2027","study_completion_date":" 08/19/2027","last_update_posted":"2024-06-10"},{"id":"1788a971-b59e-4d18-8491-8b3660158e2a","acronym":"Celestimo","url":"https://clinicaltrials.gov/study/NCT04712097","created_at":"2021-01-19T20:52:38.545Z","updated_at":"2024-07-02T16:34:59.065Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma","source_id_and_acronym":"NCT04712097 - Celestimo","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 474","initiation":"Initiation: 10/27/2021","start_date":" 10/27/2021","primary_txt":" Primary completion: 08/25/2025","primary_completion_date":" 08/25/2025","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2024-06-04"},{"id":"2d189d8c-95d4-4063-96bb-7adb6463bde6","acronym":"","url":"https://clinicaltrials.gov/study/NCT06249191","created_at":"2024-02-08T15:19:53.031Z","updated_at":"2024-07-02T16:34:59.457Z","phase":"Phase 1/2","brief_title":"Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT06249191","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" MYC","pipe":"","alterations":" ","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-06-03"},{"id":"eaa4b0cc-1c12-4c08-bcab-722de6ee0d54","acronym":"GO40554","url":"https://clinicaltrials.gov/study/NCT03677154","created_at":"2021-01-18T18:02:02.678Z","updated_at":"2024-07-02T16:34:59.656Z","phase":"Phase 1/2","brief_title":"Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT03677154 - GO40554","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 188","initiation":"Initiation: 05/23/2019","start_date":" 05/23/2019","primary_txt":" Primary completion: 08/03/2025","primary_completion_date":" 08/03/2025","study_txt":" Completion: 08/03/2025","study_completion_date":" 08/03/2025","last_update_posted":"2024-05-31"},{"id":"85ba2344-6655-424e-8ef6-730891c2fe15","acronym":"","url":"https://clinicaltrials.gov/study/NCT05412290","created_at":"2022-06-09T13:55:36.659Z","updated_at":"2024-07-02T16:35:02.336Z","phase":"Phase 1","brief_title":"Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma","source_id_and_acronym":"NCT05412290","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 12/22/2022","start_date":" 12/22/2022","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2024-05-21"},{"id":"90e45678-84d1-4b47-a66b-d3af7d734dab","acronym":"MorningSun","url":"https://clinicaltrials.gov/study/NCT05207670","created_at":"2022-01-26T13:53:53.735Z","updated_at":"2024-07-02T16:35:02.328Z","phase":"Phase 2","brief_title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","source_id_and_acronym":"NCT05207670 - MorningSun","lead_sponsor":"Genentech, Inc.","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 345","initiation":"Initiation: 02/01/2022","start_date":" 02/01/2022","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2024-05-21"},{"id":"18ee0f81-3adf-4bd7-8334-4d0c4101af0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886036","created_at":"2023-11-15T20:15:29.821Z","updated_at":"2024-07-02T16:35:07.221Z","phase":"Phase 2","brief_title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma","source_id_and_acronym":"NCT05886036","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • PD-1 • PD-L2","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • PD-1 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Lunsumio (mosunetuzumab-axgb) • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/23/2024","start_date":" 01/23/2024","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2024-04-29"},{"id":"5d730113-91fb-4659-9685-192e70066358","acronym":"","url":"https://clinicaltrials.gov/study/NCT04313608","created_at":"2021-01-18T20:54:30.933Z","updated_at":"2024-07-02T16:35:13.054Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma","source_id_and_acronym":"NCT04313608","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Gazyva (obinutuzumab) • oxaliplatin • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 06/04/2020","start_date":" 06/04/2020","primary_txt":" Primary completion: 10/26/2021","primary_completion_date":" 10/26/2021","study_txt":" Completion: 10/26/2021","study_completion_date":" 10/26/2021","last_update_posted":"2024-03-25"},{"id":"412d5cd2-47b4-4518-9ce1-4e2f34ef6a7b","acronym":"BrUOG 401","url":"https://clinicaltrials.gov/study/NCT04792502","created_at":"2021-03-11T12:53:42.451Z","updated_at":"2024-07-02T16:35:18.890Z","phase":"Phase 2","brief_title":"Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma","source_id_and_acronym":"NCT04792502 - BrUOG 401","lead_sponsor":"Brown University","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 07/14/2022","start_date":" 07/14/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-02-19"},{"id":"6484b4c0-0f7f-4382-8109-69c83a36847e","acronym":"GO40515","url":"https://clinicaltrials.gov/study/NCT03677141","created_at":"2021-01-18T18:02:02.169Z","updated_at":"2024-07-02T16:35:20.830Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03677141 - GO40515","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 03/08/2019","start_date":" 03/08/2019","primary_txt":" Primary completion: 10/12/2023","primary_completion_date":" 10/12/2023","study_txt":" Completion: 10/12/2023","study_completion_date":" 10/12/2023","last_update_posted":"2024-02-06"},{"id":"06c0193b-37f9-4bbb-98c3-e750bce1655e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05961696","created_at":"2023-07-27T18:09:10.851Z","updated_at":"2024-07-02T16:35:34.109Z","phase":"Phase 1","brief_title":"A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05961696","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/05/2023","start_date":" 07/05/2023","primary_txt":" Primary completion: 10/03/2023","primary_completion_date":" 10/03/2023","study_txt":" Completion: 10/03/2023","study_completion_date":" 10/03/2023","last_update_posted":"2023-10-10"},{"id":"6817ade8-2b47-4eca-9afd-b28ec20d68bb","acronym":"MARSUN","url":"https://clinicaltrials.gov/study/NCT06006117","created_at":"2023-08-23T16:10:50.844Z","updated_at":"2024-07-02T16:35:35.484Z","phase":"Phase 3","brief_title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","source_id_and_acronym":"NCT06006117 - MARSUN","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" CD200 • ITGAX","pipe":" | ","alterations":" CD200 expression","tags":["CD200 • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD200 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • bendamustine • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 09/05/2023","start_date":" 09/05/2023","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2023-09-27"}]